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ABSTRACT Nuclear receptor (NR) ligands occupy a pocket that lies within the core of the NR ligand-binding domain (LBD),
and most NR LBDs lack obvious entry/exit routes upon the protein surface. Thus, signiﬁcant NR conformational rearrangements
must accompany ligand binding and release. The precise nature of these processes, however, remains poorly understood.
Here, we utilize locally enhanced sampling (LES) molecular dynamics computer simulations to predict molecular motions of
x-ray structures of thyroid hormone receptor (TR) LBDs and determine events that permit ligand escape. We ﬁnd that the natural
ligand 3,5,39-triiodo-L-thyronine (T3) dissociates from the TRa1 LBD along three competing pathways generated through i),
opening of helix (H) 12; ii), separation of H8 and H11 and the V-loop between H2 and H3; and iii), opening of H2 and H3, and
the intervening b-strand. Similar pathways are involved in dissociation of T3 and the TRb-selective ligand GC24 from TRb; the
TR agonist IH5 from the a- and b-TR forms; and Triac from two natural human TRb mutants, A317T and A234T, but are
detected with different frequencies in simulations performed with the different structures. Path I was previously suggested to
represent a major pathway for NR ligand dissociation. We propose here that Paths II and III are also likely ligand escape routes
for TRs and other NRs. We also propose that different escape paths are preferred in different situations, implying that it will be
possible to design NR ligands that only associate stably with their cognate receptors in speciﬁc cellular contexts.
INTRODUCTION
The nuclear-receptor (NR) superfamily of transcription fac-
tors includes receptors for thyroid hormone (TH), retinoids,
steroids, vitamin D, xenobiotics, fatty acids, bile acids and
cholesterol derivatives, and orphan receptors for which
ligands have not been identiﬁed (1–3). NRs play widespread
roles in development, homeostasis, and disease and, conse-
quently, are major targets for pharmaceutical development.
NRs are composed of three domains, named the N-terminal
domain, DNA-binding domain (DBD), and a discrete
C-terminal ligand-binding domain (LBD) (1). The LBD
consists of ;250 residues and is the most highly conserved
domain in NRs. Apart from ligand binding, it contains
dimerization surfaces and cofactor binding sites. The DBD is
formed by ;70 residues, which fold into two zinc-ﬁnger
motifs, and is responsible for recognizing speciﬁc DNA
response elements. The N-terminal domain varies markedly
between receptors. It may contain from 24 residues (vitamin
D receptors) up to more than 600 residues (mineralocorticoid
receptors). The N-terminal domain contains ligand-depen-
dent and ligand-independent transactivation functions (1).
To some extent, the three domains are modular to the point
that the LBD of one receptor can be linked to the DBD of
another receptor in such a way that the hybrid receptor
maintains activity, responds to the hormone of one receptor,
and regulates the transcription of the gene of the second
receptor (4). NR ligands bind to the LBD, thereby inﬂuenc-
ing NR subcellular localization, coregulator recruitment,
oligomerization, and activities of the receptor N-terminal and
DBDs (5). X-ray structures of many NR-LBDs reveal that
the ligand is completely buried in the hydrophobic core of
the domain. However, most NR-LBD structures lack obvious
entry/exit routes for the ligand (1,2,6–8). Thus, signiﬁcant
conformational rearrangements must accompany ligand
entry and exit from the enclosed pocket. The portion of the
estrogen receptor (ER) and peroxisome proliferator activated
receptor (PPAR) LBDs that envelopes the ligand becomes
highly disordered in the absence of ligand and may even
adopt a highly mobile molten globular state (9–12). Thus,
ligand entry and exit probably involve rearrangements within
this part of the LBD. The precise nature of these rearrange-
ments is not understood.
Analysis of static x-ray crystal structures of NR LBDs
suggests one possible entry/exit route. Comparisons of NR
LBDs in complex with agonists or antagonists, and a few
available unliganded LBDs, reveal that ligand induces tight
packing of the LBD C-terminal helix (H) 12 against the body
of the receptor (13,14). This event occludes part of the speciﬁc
corepressor-binding site that forms on the unliganded NR
surface and induces formation of coactivator binding site on
the liganded NR surface, thereby inﬂuencing gene expres-
sion (15). It is proposed that repositioning of H12 also
regulates access of ligand to the pocket. Ligand would enter
the pocket under H12, which then folds over and traps the
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ligand until H12 becomes displaced and ligand is released
(16–18). Accordingly, many studies document a functional
connection between the NR H12 agonist position and stable
ligand binding. Factors that stabilize H12 usually reduce
rates of ligand dissociation, and factors that destabilize H12
increase rates of ligand association (9,11,12,19,20).
Analysis of NR structures suggests that there may be
other possibilities. Determination of temperature factors
(B-factors) within TR x-ray crystal structures, which provides
information about the distribution of electron density and
serves as an indirect indication of protein mobility, reveals
that the H1–H3 loop region and the associated b-sheets
are highly ﬂexible (6,21–25). Further, the surfaces of the
liganded retinoic acid receptor (RAR) and both unliganded
and liganded PPAR LBDs exhibit visible cavities with-
in the H1–H3 loop/b-sheet regions (16,26). Thus, the
H1–H3 loop/b-sheets could harbor a site of ligand entry
or release (6).
At best, however, x-ray crystal structures represent snap-
shots of particular protein conformations and provide only
limited information about mobility. Further analysis of single
x-ray crystal structures is unlikely to help us distinguish 1)
whether H12 or the H1–H3 loop region represents a plausible
entry/exit route for various NRs, 2) whether other entry/exit
routes exist, and 3) the dynamic structural alterations in-
volved in ligand entry and exit.
Molecular dynamics (MD) simulations methodologies have
been used for the study of the molecular mobility of proteins
in several contexts with great success and can be modiﬁed to
examine interactions of proteins with their cognate ligands
(17,28–31). Two groups have applied different MD tech-
niques to examine how retinoic acid (RA) might dissociate
from the RAR LBD. Karplus and colleagues used a technique
called locally enhanced sampling (LES) MD, which detects
random ﬂuctuations in the protein structure that permit
buried ligands to escape, and concluded, essentially, that RA
dissociates through a single exit channel formed by opening
of H12 (17). Schulten and colleagues employed a technique
called steered MD, in which ligand is forced out of the pro-
tein along particular paths proposed by the investigator, and
concluded that ligand could either escape under H12 or
through expansion of the small surface aperture near the H1–
H3 loop (31). Thus, MD simulations conﬁrm that the RAR
H12 region contains one likely site RA entry/exit route, but
studies of Schulten et al. suggest that RA can dissociate through
at least one alternate pathway.
The application of MD methodologies to the problem of
ligand dissociation from NRs is subject to some limitations.
First of all, every simulation requires an adequate initial struc-
ture, which usually can be obtained from crystallographic
models. The quality of these structures depends on their re-
solution and completeness and may possibly be affected by
crystal packing effects on the observed structures. Further-
more, ligand dissociation dynamics is extremely slow in
comparison to the timescales accessible to current simulation
techniques and computer resources: The mean residence
time (half-life) of the ligand inside the LBD is of several
minutes (32), which is several orders of magnitude longer
than the longest simulations ever reported to date. This
does not mean necessarily that the actual event of ligand
dissociation takes so long, but it is clear that conformational
sampling cannot be done effectively in a conventional MD
simulation. Other well-known shortcomings also affect the
simulations of proteins: the use of classical effective poten-
tial energy functions, which ignores quantum effects (e.g.,
proton transfer), the lack of knowledge about the protonation
state of acid and basic residues, which is particularly critical
for histidine residues, and the need for a realistic modeling of
the solvent, to name a few. Despite that, MD simulations can
provide valuable insights into the complex dynamical be-
havior of the NRs.
The thyroid hormone receptor (TR) has received consider-
able attention in terms of LBD structure and pharmaceutical
development (6,21–25,27,33,35). There are two TR iso-
forms, named TRa and TRb, which are products of different
genes. The LBDs of these two isoforms share 86% similarity
in their amino acid sequences and the DBDs are 88% similar,
but there is no similarity between their N-terminal domains.
The LBDs of both isoforms contain ;260 residues, which
correspond to ;60% of these receptors’ full length. Their
structures are very similar and, in particular, only a single
amino acid residue differs in their ligand-binding pocket
(22). Both isoforms bind to the same natural ligands T3 and
T4 (Fig. 1, a and e) but are found in different concentrations
in different tissues. TRb is found particularly in the liver,
whereas TRa is found predominantly in the heart. The pos-
sibility of modulating the receptor activities separately is of
great pharmaceutical value. For instance, TH analogs that
bind selectively to TRb, such as IH5, GC-24, or GC-1 (Fig.
1, c, d, and f ), reduce body fat content and circulating levels
of cholesterol, triglycerides, and lipoprotein Lp(a) without
eliciting other unwanted effects of THs (34,36–40). TR
antagonists could act as rapid treatments for elevated TH
(hyperthyroidism) and for cardiac arrhythmias (14,33,41).
Improved understanding of the steps involved in formation
of stable TR-ligand complexes and the subsequent dissoci-
ation of ligand should be helpful for developing these classes
of compounds and other NR ligands. The LBDs of both TR
isoforms have been crystallized in complex with the major
form of TH (triiodothyronine, T3) and several alternate
agonists (6,21–23,27,33–35). Also available are structures of
TRb mutants that arise in an inherited human disease, TH
resistance syndrome (RTH), and exhibit enhanced rates of T3
dissociation in vitro (24,25).
In this work, we apply a slight variant of the LES MD
simulation technique to several representative TR structures
to assess likely pathways of ligand dissociation. We detect
three competing ligand escape paths from TRs: one near
H12, one that involves rearrangements in the H1–H3 loop/
b-sheets, and a novel escape route that involves formation
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of an aperture between H8 and H11. We propose that these
pathways are general for the NR family but that different
pathways may predominate in different contexts. Overall, we
report here results of nearly 70 LES MD simulations and
discuss the implications of our ﬁndings within the context of
recent experimental works on the mechanisms of ligand bind-
ing and dissociation from NRs.
METHODOLOGY
X-ray crystal structures
Coordinates for LBD structures used in the simulations were obtained from
Prof. Robert Fletterick’s laboratory home page for TRa1 isoform reﬁned
to 2.0 A˚ resolution (6); the Protein Data Bank for structures of TRa1 bound
to IH5, TRb bound to IH5 and GC24, and the Triac-bound mutants
TRbA234T and TRbA317T (PDB ids and resolution: TRa1-IH5: 1NAV,
2.5 A˚; TRb-IH5: 1NAX, 2.7 A˚; TRb-GC24: 1Q4X, 2.8 A˚; TRb-A234T-
Triac: 1NQ0, 2.4 A˚; TRb-A317T-Triac: 1NQ2, 2.4 A˚) (24,25,27); and our
unpublished data for TRb bound to T3 at 2.6 A˚ resolution. Some missing
residues were modeled in all structures, particularly the V-loop in TRb
structures. Structures were locally minimized with the LBFGS (42) opti-
mization algorithm to relieve bad contacts in the computer package TINKER
(43). Fig. 4 was built with Molscript (44) and Raster3D (45). Figs. 5 and 6
were built with the Visual Molecular Dynamics package (VMD) (46). The
probe radius used to build the surfaces on Fig. 5 was 1.4 A˚, which is the
default value in VMD.
MD simulations
All simulations were performed with the TINKER package (43). Before any
data analysis, we performed 100 ps simulations on minimized structures
with thermalization at every 1 ps at room temperature (300 K) for all
structures with one ligand. These thermalized structures were used as
starting conﬁgurations for the control simulation and for simulations pre-
sented here with multiple copies (LES). The control simulations, aimed
at testing the overall validity of our model (Fig. 2), were conducted in the
NVE ensemble using conventional MD techniques for one ligand copy and
lasted 1 ns.
All LES simulations were performed in the NVE ensemble with the
velocity Verlet algorithm to integrate the equations of motion (47). Short
range van der Waals interactions were cut off at 9 A˚. No cutoff was used for
electrostatic interactions (all interactions were directly computed). The
systems comprised the ligands and the protein in vacuum, so no periodic
boundary conditions were applied.
FIGURE 2 Accessing the validity of the simula-
tions. (a) Convergence of the cumulative mean-square
displacement per atom in the control simulation (see
Methodology). The small slope of the line that best ﬁts
the curve in the last 200 ps (0.27 A˚ ns1) shows that
the observed mobility is due to ﬂuctuations around an
average structure. (b) MD simulations reproduce rel-
atively well the molecular mobility in TRs. Compar-
ison of B-factors obtained from the TRa1 crystal
structure with those observed in the 1 ns control MD
simulation performed with the TRa1 crystal structure.
FIGURE 1 Structures of TR ligands. Simu-
lations were done with (a) T3, (b) Triac, (c) IH5,
and (d ) GC24. The ligand T4 (e) is an important
natural ligand, and the ligand GC1 (f ) is
a synthetic TRb-selective agonist.
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Measures of protein mobility in the
control simulation
Time-averaged cumulative root mean-square deviation
We use the cumulative, time-averaged, root mean-square deviation (RMSD)
to probe the convergence of the ﬂuctuations experienced by the protein in the
control simulations. The RMSD is computed by summing the deviation of
all atoms from the initial structure from the start of the simulation (t ¼ 0)
up to time t and dividing by t: ÆRMSDæðtÞ ¼ ð1=t3 natomsÞ
R t
0
+
atoms
jx~ðtÞ  x~ð0Þjdt: If the observed mobility results from ﬂuctuations around an
average structure, ÆRMSDæ must be constant for large t, otherwise it is
expected to increase steadily.
Calculation of temperature factors
The Debye-Waller factor (Temperature factor, B-factor) corresponds to the
theoretical temperature factor given by the mean-square deviation of atomic
positions, namely, B ¼ ð8=3Þp2ÆðDrÞ2æ: We have computed B from MD
control simulations and compared it to the experimental temperature factors
according to previously published protocols (31).
LES simulations
LES simulations were proposed by Elber and Karplus and applied originally
to the problem of carbon monoxide escaping through myoglobin (28). The
method is designed to the study of the molecular motions of a small part (e.g.,
a ligand) of a given large molecular system (the ligand-protein complex). To
obtain a broader sampling of the structure and dynamics of the system, the
subset of interest is replicated and the simulation is performed for the
replicated set in the presence of a unique copy of the rest of the system. This
method has been extensively used to study ligand diffusion through globins,
and several results were conﬁrmed experimentally (48–50). In a ligand-
protein complex, for example, the ligandmay be replicated several times. The
ligands do not interact with each other, and the protein-ligand interactions are
scaled according to the number of ligands present. Since there are several
copies of the ligand, the probability of observing a rare event (e.g., ligand
dissociation) is increased. Furthermore, since the ligand-protein interactions
are scaled by the number of copies, the energy barriers that must be overcome
to observe ligand dissociation are also decreased, and therefore the ligand
dissociation rates are increased exponentially (51). There have been important
theoretical developments of the LES technique: Straub and Karplus have
shown that energy equipartition is not satisﬁed by the conventional imple-
mentation of LES and that the kinetic energy of the ligands increases as the
number of ligands increase (52). Ulitksy and Elber have shown that time-
dependent and several thermodynamic properties are not well represented by
LES. They have proposed a correction to LES (cLES) that increases the ac-
curacy of the temperature distribution and yields the correct time-dependent
properties of the enhanced sampled subset of the system (51,53). They have
shown, for instance, that the diffusion rates are well reproduced by cLES, as
opposed to the conventional LES technique, which yieldsmuch faster diffusion.
The NR-LBD-ligand complex possesses some very particular properties
that dictate the choice of a suitable form of the LES implementation: First, in
this type of problem one wishes primarily to search for likely pathways for
ligand escape from the LDB pocket. Second, ligand dissociations from the
protein are regarded as rare events, given that the (inverse) escape rate is
experimentally determined to be several minutes (23). Therefore, to observe
dissociation in a simulation, the technique must provide three main features:
i), the enhanced sampling provided by the number of ligand copies, ii),
lowering of the energy barriers provided by the reduced potentials, and iii),
faster diffusion rates. The necessity of large diffusion rates prevents us from
using the corrected cLES method of Ulitsky and Elber (notice that cLES was
not used either in the study of RA dissociation from its NR (17)).
Furthermore, the ligands are relatively large (29–51 atoms in our case) and
have several intramolecular degrees of freedom. Thus, the shortcomings
associated with high subsystem temperatures should be avoided for the
ligands internal motions as well. Following these guidelines, we have
implemented a variant of the LES method in the TINKER (43) package in
which the ligand-protein (and protein-ligand) interaction potentials are
divided by the number of copies, whereas the interaction between ligands is
null. The masses of the ligands are not scaled, and the intramolecular
potentials of the ligands and of the protein amino acids are treated as full
potentials. In this way, the dynamics of the system is fully Newtonian and
the average kinetic energy per atom is 3kBT/2, independent of the number of
the copies used (energy equipartition is satisﬁed). Unlike cLES, the
drawback of our implementation is that the dynamics of the ligand copies
will not be mapped onto the dynamics of a single-ligand protein system.
Therefore, although energy equipartition is satisﬁed, the time-dependent
properties will not correspond to the time-dependent properties of a
conventional ligand-protein system. This implementation is related to the
thermalization scheme proposed by Straub and Karplus to overcome the
energy equipartition problem for nonNewtonian systems (17,27,28,52).
From our implementation we would not expect to observe the time depen-
dence of ligand escape, but we certainly hope to provide valuable structural
insights into the mechanisms of ligand dissociation from the TRs.
Initial atom velocities are randomly attributed according to the Boltzmann
distribution for the desired temperature of 300 K. The kinetic energy (and,
hence, total energy) of the system increases with the number of ligand copies.
Individual hormone and protein atoms are explicitly treated; i.e., all atoms
were included in theMD simulations. The potential energy parameters for the
protein atoms were obtained from the OPLS-AA force ﬁeld for protein
simulation (54). Simulations were performed with the minimum number of
ligands such that dissociationwas observed in the timescale of our simulations
(;150 ps), namely, 10–50 copies of the T3 and 50 copies of other ligands.
We also performed LES simulations of dissociation of 9-cis-retinoic acid
dissociation from the RAR (not shown; part of these results appeared in
Sonoda et al. (55)). Our simulations use OPLS-AA force ﬁeld parameters,
whereas previous studies used CHARMMparameters (17). Nevertheless, we
observedRAdissociation through Path I in similar timescales, suggesting that
simulated ligand dissociation pathways are independent of details of force
ﬁeld parameters and that our implementation of LES (55,56) can be directly
compared to those of others (17).
Ligands
Our simulations treat the ligands as fully ﬂexible molecules. The van der
Waals and torsional parameters for the T3, IH5, GC24, and Triac molecules
were obtained by group analogy in the OPLS-AA set (57), except for the
iodine atoms for which the van der Waals interaction parameters are those
reported in Blaney et al. (58). Partial atomic charges for T3 and Triac were
computed from the optimized structure at the MP2/Lanl2DZ level of theory.
This basis set was chosen because of the iodine atoms in these ligands.
Charges for IH5 and GC24 were calculated from the optimized structures
at the Hartree-Fock 6-31G(d,p) level of theory. All ab initio calculations
were performed with Gaussian98 (59). The charges for T3 and Triac were
computed with the Mulliken protocol because ESP ﬁtting protocols such as
Merz-Kollman or ChelpG are not parameterized for iodine. Although the use
of ESP charges is recommended for the OPLS force ﬁeld, the use ofMulliken
charges in this case is not critical due to the approximate character of the
interaction between the ligands and the protein. The charges for IH5 and
GC24 where computed by the Merz-Kollman scheme. All the parameters are
supplied as Supplementary Material.
RESULTS AND DISCUSSION
MD simulations reproduce observed molecular
mobility in TRa
First, to address whether the mobility of the protein struc-
ture observed in our control simulation is a consequence of
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ﬂuctuations around an average structure (and not a constant
drift from the initial structure), we have computed the cumu-
lative time-averaged root mean-square displacement. Such a
measure of the mobility must converge if the protein motions
are characterized by ﬂuctuations around an average structure.
As shown in Fig. 2 a, our 1 ns control simulation exhibits a
ÆRMSDæ(t) drift of only 0.27 A˚ ns1 for the last 200 ps,
revealing that, indeed, there is no signiﬁcant drift of the
positions from the initial structure and, therefore, the mobility
observed is reasonably well converged.
Since the temperature factors (B-factors) observed in
actual crystal structures represent one indication of protein
mobility, it is possible to obtain a crude indication of whether
MD simulations provide realistic information about actual
protein mobility by comparing motions observed in MD
simulations with B-factors derived from the crystal structure.
The results of such a comparison, performed with the rat
TRa1 LBD in complex with T3 resolved to 2.0 A˚ (6), are
shown in Fig. 2 b. Overall, the same areas of TRa that
exhibit high mobility in the simulation also exhibit high
B-factors in the crystal, indicating that our MD simulations
provide useful information about the TR-LBD mobility.
Some discrepancies are clearly present. Surface amino acids
Pro193-Ser199 (H2) and Ile360-Trp364 (top of H11) display
higher mobility in the simulation than in the crystal. This is
likely due to the fact that both regions of the TR-LBD engage
in contacts with neighboring LBDs in the crystal (6), as
opposed to our TR monomer structure simulations in which
these contacts are obviously absent. This simulation also
conﬁrms that the overall structure of the protein is conserved
even in vacuum in the timescale of the simulations presented
here. As already mentioned, conventional MD simulations
do not detect dissociation of buried ligands from proteins;
these events occur on timescales that are beyond the reach of
current computing techniques. Accordingly, we did not
detect dissociation of bound T3 from the TRa-LBD during
the 1 ns control simulation.
To test our LES simulations for unphysical results (for
instance, unphysically close contacts), we have computed
the intermolecular interaction energy of the system while
varying the number of copies. We have not found any unre-
alistic intermolecular interaction energies for any number of
ligand copies (Supplementary Material, Fig. S1).
Three pathways for T3 dissociation from TRa1
We performed several sets of LES simulations with the TRa1
crystal structure, described above, in the presence of 10–50 T3
copies. Ligand dissociation was detected frequently and in-
volved rearrangements of the region of the LBD that envelops
T3. More surprisingly, T3 dissociated from the LBD via three
distinct routes rather than a single preferred pathway. A
schematic of Paths I–III is shown in Fig. 3. Ligands dissociate
either i), through a space between H3 and H11 that lies under
H12 and is vacated by repositioning of H12 as predicted by
models described in the Introduction; ii), betweenH8 andH11
and the V-loop in a pathway that has never previously been
observed in MD simulations or predicted from analysis of
static protein structures; or iii), through an aperture between
H3, the b-hairpin formed by b-sheets S3 and S4, and the loop
between H1 and H2 and analogous to previously proposed
entry or escape routes within this region of TR, RAR, and
PPAR LBDs (6,16,26). Path I was observed most commonly
in our simulations (14 times in 33 simulations performedwith
T3), Path II relatively infrequently (6 times in 33 simulations),
and Path III almost as frequently as Path I (10 times in 33
simulations) (Table 1).
Ligand escape cavities
The precise events that result in formation of ligand escape
cavities and the nature of these cavities as observed in our
simulations are described in detail in this section. As dis-
cussed previously, the reliability of the simulations decreases,
while the positions of the ligands diverge. Therefore, our
analysis considers two phases of the simulations separately.
The very ﬁrst stages of the simulations, when the ligands
approximately share the same positions, are employed to
FIGURE 3 Schematic representation of
the three paths. (a) In Path I, H3 breaks
down in two helices and H12 swings apart
from it, forming the escape cavity. (b) The
joint bending of H8 and the V-loop away
from H11 allows ligand escape in Path II.
(c) In Path III, the breakdown ofH3 allows
for the formation of a cavity between it and
the b-hairpin through which ligands
escape. Arrows indicate protein move-
ments that from the bound sturcture
(dotted) allow the ligands to escape.
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identify the protein-protein contacts that are broken to form an
aperture in the protein surfacewhich permits ligand escape.We
propose that the residues involved in these contacts should be
explored in detail by mutational analysis or by means of other
simulation techniques. Second, we describe the overall
aspects of the pathways encountered, which include protein
motions that take place after the dissociation of several
ligands. Interpretation of these motions requires care, since
the ﬂuctuations may be a consequence of the systems
approximations. These ﬂuctuations provide insights into the
stability of different parts of the protein but may not be
interpreted as movements that one would actually expect in
a real system.
Dissociation along Path I
Path I involves displacement of H12 (Figs. 3 a and 4 a). The
sole difference between events observed here and in previous
simulations performed with RARs is that TRa H3 breaks
into two segments during the simulation, whereas RAR H3
tends to stiffen and forms an extended a-helix ((17), data not
shown, see Discussion). Outward motion of the N-terminal
H3 segment helps to create the escape route.
The rearrangements that lead to ligand escape involve the
regions of the TR that pack against the ﬁrst thyronine ring of
the ligand (6). First, H12 and the associated H11–H12 loop
dislocate from H3. This is followed by simultaneous rear-
rangements in H12 and H3: i), H12 undergoes denaturation
and unwinding between amino acids Leu400–Phe405. Phe405,
which lies on the inner face of H12 and contacts ligand
directly in the TR structure, faces inward toward the pocket
throughout the simulation; and ii), H3 breaks into two helices,
which are preserved throughout the remainder of the sim-
ulation, separated at amino acid residues Thr223 and Pro224.
The lower portion of H3 moves outward, opening up the
interior of the LBD. Denaturation of H12 and breakdown of
H3 are followed by further dislocation of the H11–H12 loop
(Thr394–Pro399) from the lower part of H3 (Ala214–Thr223) as
H3 moves outward. T3 ﬁnally passes through the cavity
formed between the H11–H12 loop and the lower part of H3.
The Path I escape cavity is shown in detail in Fig. 5 a.
Essentially, the cavity is formed by disruption of hydrophobic
interactions between Thr223 on H3 and Leu400 on H12 and
between Thr219 (from H3) and Pro398 and Leu396 (both in the
H11–H12 loop) asH3 pulls away from theH11–H12 loop and
H12.
Dissociation along Path II
The main features of Path II are separation of H8 and H11
and concurrent dislocation of the associated V-loop that
links H2 to H3 (residues Pro200–Asp211) (Figs. 3 b and 4 b).
V-loops are frequently found in globular proteins and have
been reported in a number of instances to work as ‘‘lids’’ to
control enzyme substrate binding and release (60).
The regions of TR that rearrange in ligand escape (H11
and H8) participate in hydrophobic interactions with the
phenyl rings of the ligand, and His381 on H11 also forms
a hydrogen bond with the ﬁrst thyronine ring. The dynamics
of the pathway evolve as follows: H11 undergoes local de-
naturation at residues Gly378 and Ala379. The integrity of H8
is preserved, but H8 residues Val295–Ala308 swing apart from
H11 as the ligand moves between the helices, disrupting their
native contacts. The V-loop bends together with H8 as it
pulls apart from H11, as seen in Figs. 3 b and 4 b. Val295 on
H8 hydrogen bonds with the side chain of Asp208 at the start
of the simulation, and this contact is preserved throughout
the rest of the simulation, leading to joint displacement of H8
and the V-loop.
The escape cavity is shown in detail in Fig. 5 b. Cys380
(H11), in close contact with Val295 and Arg284 (H8) at the
start of the simulation, pulls apart from both of these amino
acids thereby permitting ligand escape. The cavity border
comprises mostly hydrophobic residues: Cys380, Ser383,
Arg384, Ile377 (H11), and Val295, Ile299 (H8).
Dissociation along Path III
Path III involves a region of TRa that was previously pro-
posed to represent a ligand entry route (6) and strongly
resembles the mechanism proposed for the dissociation of
RA from RARg on the basis of steered MD simulations by
Schulten et al. (31). Here, ligands leave on the opposite side
of the receptor from H12 via an aperture formed between H3,
the b-hairpin formed by b-sheets S3 and S4, and the loop
between H1 and H2 (Figs. 3 c and 4 c).
The speciﬁc residues directly involved in Path III are
within the H1–H2 loop (Thr178–Gly182), the lower
(N-terminal) portion of H3 (Lys220–Val229), and the b-hairpin
(Thr275–Met280). Several amino acids that directly contact
T3 (Ile
221, Ile222, Ala225, Arg228, and Leu276) also participate.
The dynamics of the pathway evolve as follows: H3 breaks
into two helices—residues Leu212–Pro224 and Ile226–Lys234,
TABLE 1 Escape paths found in separate MD simulations
with TRa-T3
Number of copies Escape paths found
13 II —* I
14 III II III
15 I I I
16 I I —*
17 I III I
18 II III III
19 —* II I
20 III II I
25 III I III
50 I I III I IIy III
Three simulations were performed with 13–25 copies, and six simulations
were performed with 50 copies, as shown.
*No escape found during the entire course of the simulations (;150 ps).
yIn this simulation, three copies left the binding pocket through Path I,
whereas the other 47 left through Path II.
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as observed for Path I. The lower helical portion of H3
(amino acids 212–224) dislocates from the associated
b-hairpin and moves outward. The internal structure of the
b-hairpin is conserved while it becomes displaced and moves
away from H3 (Figs. 3 c and 4 c).
The escape cavity is shown in Fig. 5 c. The region that
unfolds is hydrophilic. Before unfolding, this region of the
TRa is stabilized by hydrogen bonds between different
amino acid residues and between amino acid residues and
the carboxyl group of the ligand (6,22). In particular, the hy-
drophilic interaction between Arg228 (in the pocket at the top
of H3 and in contact with the carboxyl group of the ligand at
the start of the simulation) and the side chain of Ser277 (in the
pocket in the b-sheets) is broken during ligand escape, and
FIGURE 4 Three ligand escape paths.
Snapshots of the simulations showing global
views of the paths found for T3 escape from
TRa1 are on the right. Corresponding views
of the crystallographic structure are on the
left. (a) Path I, (b) Path II, and (c) Path III. T3
molecules are shown as lines on the left and
as ball and sticks on the right. Some T3
replicas were omitted for clarity.
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these residues eventually form opposite ends of the escape
cavity at the end of the simulation. Interactions between
Ser277 and Pro224 (H3) and Arg228 and Ala180 (H1–H2 loop)
are also lost. The resulting loss of contacts between Pro224
and surrounding residues probably increases the helix
breaking activity of the Pro residue and facilitates H3 dis-
ruption, an essential feature of this pathway. Each of the
aforementioned amino acid residues and residues Ile221,
Asn179, and Thr178 form the border of the cavity that permits
ligand escape. Unlike escape cavities involved in Paths I and
II, the Path III escape cavity is hydrophilic and will be more
favored in aqueous solution.
FIGURE 5 Formation of ligand es-
cape cavities. The relative position of
amino acids residues are presented in
the crystallographic structure (left) and
in a snapshot of the initial stages of the
simulation (right). The images are from
(a) Path I, (b) Path II, and (c) Path III.
Different ligand (T3) copies are shown
by sticks.
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Different escape pathways predominate in
different TR structures
Next, we investigate whether Paths I–III are general for both
a- and b-TRs and alternate TR ligands by performing LES
simulations with structures of TRb in complex with T3 (I.
Polikarpov, unpublished) and the highly TRb-selective TR
agonist GC-24 (27), and with structures of both TR isoforms
in complex with the high afﬁnity TRb-selective agonist IH5
(Pdb IDs 1NAV; 1NAX). In addition, we performed simu-
lations with structures of two human TRb mutants, A234T
and A317T, that arise in the human syndrome of resistance to
thyroid hormone (RTH) and exhibit increased rates of ligand
dissociation in vitro (24,25). Simulations were performed six
times with 50 copies of each ligand and utilized x-ray crystal
structures that were reﬁned to high (2.4–2.8 A˚) resolution
(see Methodology).
Overall, we detect the same dissociation pathways that
were identiﬁed for TRa (Table 2). Paths I and III appeared
frequently. Path II (which appeared at low frequency with
TRa) was only detected in simulations with TRb mutants
and once in a simulation that utilized a TRb/T3 model (not
shown), although this structure was solved at relatively low
resolution (3.7 A˚; PDB id. 1BSX (21)) and may not yield
reliable results. Thus, Paths I and III, at least, are common to
both TRs.
More interestingly, individual escape paths were detected
at different frequencies in different contexts (Table 2). LES
simulations performed with the TRa-T3 structural model
detect Path I and Path III in relatively even proportions and
Path II at low frequency (Table 1), but LES simulations
performed with structural models of TRb-T3 only detected
Path I (six of six simulations, Table 2). Similarly, simulations
performed with the TRa-IH5 structural model detected Paths
I and III with equivalent frequencies (each in three of six
simulations), whereas Path I predominated with the TRb-
IH5 structural model (ﬁve of six simulations). Nevertheless,
Path III predominated in simulations that utilized the TRb-
GC24 model (six of six simulations).
The TRb RTH mutants also exhibited unique preferences
for particular dissociation paths; simulations performed with
TRbA234T revealed a strong preference for Path II (six of six
simulations) and a mixture of paths for TRbA317T mutant
(Path I: two simulations; Path II: three simulations; Path III:
one simulation). Although these preferences were detected
in a small number of simulations, we suggest that they are
consistent with observed features of TRa and TRb crystal
structures and reﬂect meaningful differences in the choice of
dissociation paths (see Concluding Remarks).
CONCLUDING REMARKS
In this study, we used x-ray structures of liganded TR-LBDs
in LES simulations to identify ligand escape pathways from the
enclosed TR pocket. As expected, T3 dissociates from TRa1
through a cavity formed by dislocation of H12 from H3
and H11 (Path I). Nevertheless, T3 can also dissociate
through a completely unsuspected escape cavity formed by
joint displacement of H8, H11, and the V-loop (Path II) or
through a hydrophilic cavity formed by rearrangements
within the H1–H3 loop and associated b-sheets (Path III).
Paths I and III were also detected in auxiliary LES simula-
tions that explored dissociation of T3 and GC24 from TRb
and IH5 from both TRs, albeit at different frequencies, and
Path II was detected in simulations that utilized TRb RTH
mutants. Thus, we propose that TR ligands dissociate from
the LBD along three competing pathways, rather than via a
single entry/exit route.
Functional evidence supports the idea that TR ligands
dissociate from the LBD in more than one way. Suboptimal
packing of TR H12 over the thyroxine (T4) 59 iodine group
correlates with very high dissociation rates of T4 relative to
T3, which lacks the 59 iodine (23). Thus, destabilization of
H12 (Path I) promotes increased rates of ligand release.
Nevertheless, x-ray crystal structures of the TRb RTH mu-
tants used here reveal that increased rates of T3 dissociation
are accompanied by speciﬁc increases in disorder within the
H1–H3 loop (24,25). Thus, destabilization of the V-loop/
H1-H3 loop region (involved in Paths II and III) also pro-
motes ligand escape, as predicted in our simulations.
As described in the Introduction, NR H12 position re-
gulates ligand association and dissociation rates, and H12
covers a possible ligand entry/exit route. This is illustrated in
x-ray structures of ERa and glucocorticoid receptor (GR) in
complex with tamoxifen and RU486 (Fig. 6, a–c) (61–63).
Nevertheless, our analysis of static x-ray structures of a
number of NR-LBDs reveals features that may be consistent
with ligand escape along Paths II and III. Liganded GR and
androgen receptor (AR) LBDs lack the V-loop and only
contain a short H8 (Fig. 6, d–f ) (63–66). Both of these
features could favor ligand escape along Path II. Further,
structures of the pregnane X receptor (PXR) bound to hyper-
forin (67), farnesoid X receptor (FXR) bound to fexaramine
(65), and PPARg bound to rosiglitazone (26), reveal cavities
between the bottom of H3 and associated b-sheets in the case
of PXR and in the H1–H3 region in the case of FXR and
PPAR. This, coupled with the facts that human RTH mu-
tations which destabilize the TR H1–H3 region result in
TABLE 2 Escape pathways found for selective ligands,
different isoforms, and mutants in auxiliary simulations
System Escape paths found
TRb with T3 I I I I I I
TRb with GC24 III III III III III III
TRb with IH5 I I I I III I
TRa1 with IH5 III III I* I III I
TRb A317T with Triac II I III II I II
TRb A234T with Triac II II II II II II
All simulations here were performed with 50 copies of the ligand.
*One of the 50 copies left the binding cavity through Path III.
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increased rates of ligand dissociation (24,25), that steeredMD
simulations, indicate that RA escape from the RAR LBD
H1–H3 region is energetically favorable (31), and that Path
III uniquely involves expansion of a hydrophilic cavity that
will be favored in living cells (Fig. 5 c), suggests that Path
III is a common mode of ligand escape from many NRs.
Could the dissociation pathways described here function
in reverse as ligand association pathways? Our studies do not
address this question, but we note that NR H12 is implicated
in regulation of the rates of ligand dissociation and associa-
tion (19,20,67), whereas our preliminary results suggest that
RTH mutations that enhance ligand exit (possibly through
Paths II and III (Table 2)) enhance T3 dissociation rates but
do not affect ligand association rates (Cunha Lima, un-
published). Perhaps Path I represents a viable ligand entry
route, but Paths II and III do not.
We observe differences in relative frequencies of Paths I, II,
and III in simulations performed with different structures.
Paths I and III are detected at approximately equivalent
frequencies in simulations performed with TRa, whereas
previous LES simulations and our unpublished simulations
performed with RARs only detect Path I (17,55). The likely
explanation for this difference centers upon the tendency of
TR H3 to break into short a-helices around a unique Pro
residue not conserved in RARs (Fig. 7) or other NRs (not
shown). Disruption of TRH3 promotes ligand escape via Path
III through spaces vacated by the N-terminal portion of H3.
RARs contain a Lys residue at the equivalent position, which
lacks the propensity of Pro to disrupt a-helices, and RAR H3
stiffens during simulations to form an extended a-helix that
‘‘pinches’’ the pocket, precluding ligand escape through the
bottom of H3 and forcing RA out under H12 (17).
It is not clear whether ligand escape from RARs is truly
restricted to Path I or whether RA can escape from the H1–
H3 loop via rearrangements that are too subtle to be detected
in LES. We favor the latter possibility, since there are strong
similarities between hydrophilic escape cavities in the TR
H1–H3 region and detected in the RAR H1–H3 region in
steered MD (31).
Our simulations also detected preferences for particular
escape paths among TR isoforms, TRs in complex with dif-
ferent ligands and between wild-type TRb and TRb RTH
mutants. Each of these preferences is consistent with ob-
served features of TR structures: i), T3 and IH5 dissociate
from TRb along Path I but from TRa along Paths I and III.
This is consistent with the fact that the TRbH11–H12 region
(involved in Path I) is often less stable than the equivalent
region of TRa, as judged by B-factors (6,21–23). and ii), T3
dissociates from TRb along Path I, whereas GC24 disso-
ciates from TRb along Path III. GC24 contains a bulky 39
benzyl extension accommodated by rearrangements in H3
and H11 that extend the functional ligand-binding pocket
(27). The GC24 extension contacts regions of TR H3 and
H11 that are exposed in Path I, and we suggest that GC24
blocks Path I and favors Path III. Finally, as alluded to
above, we suggest that ligand dissociates from wild-type
TRb along Path I but from TRbA234T along Path II and
from TRbA317T along a mix of routes because RTH muta-
tions destabilize the H1–H3 loop involved in ligand exit
through Paths II and III (24,25).
The notion that TR and other NRs harbor multiple ligand
dissociation pathways, and that different pathways may pre-
dominate in different contexts, has interesting implications
FIGURE 6 Ligand-bound structures of the NR LBDs suggest the
generality of ligand escape pathways in the NR superfamily. The structures
are (a) ER-estradiol complex; (b) ER bound to the selective antagonist,
4-hydrotamoxifen; and (c) the GR-antagonist (R486) complex. (d ) GR
receptor bound to dexamethasone. (e) The AR bound to dihydrotestosterone.
(f ) Another dexamethasone-GR structural model. (g) The PXR bound to
hyperforin. (h) The FXR complexed with the high afﬁnity ligand
fexaramine. (i) The PPARg-rosiglitazone complex. Structures a–c suggest
the displacement of the H12 apart from H3 as in Path I. Structures d–f lack
theV-loop, and the ligand is solvent accessible in the region between H8 and
H11, similar to Path II. Structures g–i ligands have extensions that abut the
mobile region comprised by the H1–H3, suggesting a dissociation pathway
similar to Path III.
FIGURE 7 H3 of RA and TRs. The structurally important Pro residue,
which could be a key amino acid required to promote dissociation through
Path III, is highlighted in TR sequences.
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for NR function and pharmaceutical design; TR ligands
that are tailored to escape from the LBD along particular
pathways will exhibit context selective binding. The strong
TRb selectivity of GC24 may be related to its preference for
dissociation along Path III. Moreover, our studies assumed
isolated LBDs, although NRs form large complexes with
other coregulatory molecules that may differentially stabilize
various portions of the LBD and inﬂuence the choice of
entry/exit route. For example, coactivator binding stabilizes
H12 over the putative Path I entry/escape route. Thus, it is
possible that ligands that are committed to Path I would
dissociate very slowly from TR/coactivator complexes and
promote stable transcriptionally active TR complexes.
At the least, our simulations identify ﬂexible regions of
TR that could harbor compounds with bulky extensions such
as the GC24 39 benzyl group, accommodated within the
region of TRb that rearranges in Path I (14,27). Perhaps
other regions of ﬂexibility identiﬁed in our simulations could
also harbor bulky extensions with useful properties (14,36).
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